166 related articles for article (PubMed ID: 29845626)
1. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
2. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
4. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.
Vänskä S; Luostarinen T; Baussano I; Apter D; Eriksson T; Natunen K; Nieminen P; Paavonen J; Pimenoff VN; Pukkala E; Söderlund-Strand A; Dubin G; Garnett G; Dillner J; Lehtinen M
J Infect Dis; 2020 Aug; 222(6):948-956. PubMed ID: 32161969
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Söderlund-Strand A; Vänskä S; Paavonen J; Pukkala E; Dillner J; Lehtinen M
Int J Cancer; 2018 Jun; 142(12):2491-2500. PubMed ID: 29377141
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Natunen K; Nieminen P; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Vänskä S; Cheuvart B; Soila M; Bi D; Struyf F
Cancer Med; 2021 Nov; 10(21):7759-7771. PubMed ID: 34581025
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
10. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M; Apter D
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
[TBL] [Abstract][Full Text] [Related]
11. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
[TBL] [Abstract][Full Text] [Related]
12. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
[TBL] [Abstract][Full Text] [Related]
13. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
14. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
[TBL] [Abstract][Full Text] [Related]
19. Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial.
Kalliala I; Eriksson T; Aro K; Hokkanen M; Lehtinen M; Gissler M; Nieminen P
Prev Med; 2021 May; 146():106473. PubMed ID: 33639181
[TBL] [Abstract][Full Text] [Related]
20. Immune response following a two-dose schedule of bivalent HPV vaccination among girls and boys.
Middeldorp M; Duijster JW; van de Kassteele J; van der Klis FRM; de Melker HE
Front Immunol; 2024; 15():1327770. PubMed ID: 38343547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
